BiotechTube

ARCT-810

Phase 2Recruiting
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

OTC Deficiency

Conditions

OTC Deficiency, Ornithine Transcarbamylase Deficiency, OTCD

Trial Timeline

Nov 4, 2024 → Sep 1, 2026

NCT ID
NCT06488313

About ARCT-810

ARCT-810 is a phase 2 stage product being developed by Arcturus Therapeutics for OTC Deficiency. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06488313. Target conditions include OTC Deficiency, Ornithine Transcarbamylase Deficiency, OTCD.

What happened to similar drugs?

20 of 20 similar drugs in OTC Deficiency were approved

Approved (20) Terminated (6) Active (0)
✅PEG-somatropinSun PharmaceuticalApproved
✅PEG-somatropin + PEG-somatropinSun PharmaceuticalApproved
✅MecobalaminEisaiApproved
✅lopinavir/ritonavirAbbVieApproved
✅emtricitabine/tenofovir disoproxil fumarateMerckApproved
✅Saizen® solution for injection (referred as Saizen®)MerckApproved
✅3-drug anti-HIV therapy + RaltegravirMerckApproved

Hype Score Breakdown

Clinical
12
Activity
15
Company
5
Novelty
0
Community
0

Clinical Trials (4)

NCT IDPhaseStatus
NCT06488313Phase 2Recruiting
NCT05526066Phase 2Terminated
NCT04442347Phase 1Completed
NCT04416126Phase 1Completed

Competing Products

20 competing products in OTC Deficiency

See all competitors
ProductCompanyStageHype Score
KER-047Keros TherapeuticsPhase 2
17
SomatropinEli LillyPhase 3
40
Somatropin (recombinant deoxyribonucleic acid [rDNA] origin)Eli LillyPre-clinical
26
pegylated Somatropin + pegylated Somatropin + Jintropin AQSun PharmaceuticalPhase 2
35
PEG-somatropinSun PharmaceuticalApproved
39
PEG-somatropin + PEG-somatropinSun PharmaceuticalApproved
39
PEG-somatropinSun PharmaceuticalPhase 3
40
GSK1265744 30mg + Placebo + GSK1265744 5mgShionogiPhase 2
35
DolutegravirShionogiPhase 3
40
GSK1349572 + efavirenzShionogiPhase 2
35
Dolutegravir + Rlipivirine + GSK1265744ShionogiPhase 1
29
Dolutegravir 50 mg tablet + Dolutegravir 50 mg oral granulesShionogiPhase 1
29
Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg + Dolutegravir 50 mg + abacavir 600 mg/lamivudine 300 mgShionogiPhase 1
29
GSK1349572 (dolutegravir) + raltegravirShionogiPhase 3
40
Ortho-Cyclen + Dolutegravir + PlaceboShionogiPhase 1
29
GSK1349572 + Placebo + Iohexol Injection + Para-aminohippurate infusionShionogiPhase 1
29
dolutegravirShionogiPhase 3
40
Dolutegravir + Atripla + Abacavir/Lamivudine + Abacavir/Lamivudine Placebo + Dolutegravir placebo + Atripla placeboShionogiPhase 3
40
GSK1349572 + EfavirenzShionogiPhase 1
29
GSK1349572ShionogiPhase 1
29